According to our (Global Info Research) latest study, the global Radiopharmaceutical Solutions market size was valued at US$ 8450 million in 2025 and is forecast to a readjusted size of US$ 14442 million by 2032 with a CAGR of 8.0% during review period.
Radiopharmaceutical Solutions refer to a comprehensive system encompassing the research, development, production, preparation, distribution, and clinical application of radiopharmaceuticals. This involves combining radioisotopes with specific biomolecules (such as ligands, antibodies, or small molecules) for diagnostic imaging (PET/SPECT) or targeted therapy (RLT/TRT) of diseases.
Gross Margin Level
The gross margin of the radiopharmaceutical solutions industry is typically significantly higher than that of generic drugs, general medical consumables, and most generic formulations. This is because it's not an industry that simply profits from raw material markups; rather, it's a high-barrier-to-entry sector where value is determined by a combination of factors, including radionuclide acquisition, radiolabeling, GMP hot chamber manufacturing, timely delivery, cold chain and radiation safety management, hospital access, and clinical support. Publicly available company data supports this: Lantheus's revenue in Q1 2025 was $373 million, with a gross profit of $238 million, corresponding to a gross margin of approximately 63.8%; Telix disclosed an overall gross margin of 53% for the first half of 2025, while the core Illuccix product maintained a gross margin of 64%. Based on the publicly available performance of these leading companies, the industry's gross profit margin can be roughly understood as follows: Mature diagnostic radiopharmaceuticals and branded PET/SPECT products typically have a margin between 50% and 65%. Companies with strong distribution networks but handling more compounding and third-party sales will have slightly lower margins. Companies producing therapeutic radiopharmaceuticals, therapeutic products, high-barrier platforms for alpha/beta radionuclides, and those with capabilities in rare isotopes can theoretically maintain higher margins, but they also face greater pressure from capacity investment, quality control, and compliance costs.
Industry Drivers
The growth of this industry primarily stems from the continued rise in the global cancer burden. The WHO indicates that there were approximately 20 million new cancer cases globally in 2022, and this number is projected to exceed 35 million by 2050, a 77% increase from 2022. This directly drives the expansion of demand for tumor imaging diagnostics, precision stratification, and targeted radiotherapy. The second core driver is the accelerated commercialization of therapeutic radiopharmaceuticals, with specific data indicating that growth stems from rising cancer and cardiovascular disease prevalence, as well as increased demand for diagnostic and therapeutic radiopharmaceuticals and medical isotopes. The third driver is that therapeutic radiopharmaceuticals are growing faster than diagnostic radiopharmaceuticals; in the same report, the projected growth rate for the therapeutic nuclear medicine sub-segment is higher than that for the diagnostic sub-segment, indicating that the industry is rapidly upgrading from "image-assisted" to "precision treatment platform." Furthermore, the widespread adoption of hybrid imaging technologies such as PET/CT and SPECT/CT, the construction of nuclear medicine departments in hospitals, the expansion of isotope production capacity, and the introduction of new radionuclide platforms are all continuously boosting the industry's prosperity.
This report is a detailed and comprehensive analysis for global Radiopharmaceutical Solutions market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Radiopharmaceutical Solutions market size and forecasts, in consumption value ($ Million), 2021-2032
Global Radiopharmaceutical Solutions market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
Global Radiopharmaceutical Solutions market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
Global Radiopharmaceutical Solutions market shares of main players, in revenue ($ Million), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Radiopharmaceutical Solutions
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Radiopharmaceutical Solutions market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Novartis, Curium, Siemens, GE HealthCare, Lantheus, Jubilant Radiopharma, Cardinal Health, Telix Pharmaceuticals, ITM Isotope Technologies Munich, Bracco Imaging, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Radiopharmaceutical Solutions market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Diagnostic Radiopharmaceuticals
Therapeutic Radiopharmaceuticals
Others
Market segment by Types of Radioactive Nuclides
Radiopharmaceuticals that Emit Single Photons
Radiopharmaceuticals that Emit Positrons
Radiopharmaceuticals that Emit Beta Particles
Radiopharmaceuticals that Emit Alpha Particles
Market segment by Dosage Forms
Injectable Solutions
Oral Solutions
Granules
Others
Market segment by Application
Hospital
Specialist Clinic
Biopharmaceutical Company
Others
Market segment by players, this report covers
Novartis
Curium
Siemens
GE HealthCare
Lantheus
Jubilant Radiopharma
Cardinal Health
Telix Pharmaceuticals
ITM Isotope Technologies Munich
Bracco Imaging
Bayer
Eli Lilly
Jubilant Pharma
Aurobindo Pharma
Sinotau
Global Medical Solutions
SOFIE Biosciences
Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Radiopharmaceutical Solutions product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Radiopharmaceutical Solutions, with revenue, gross margin, and global market share of Radiopharmaceutical Solutions from 2021 to 2026.
Chapter 3, the Radiopharmaceutical Solutions competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Radiopharmaceutical Solutions market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Radiopharmaceutical Solutions.
Chapter 13, to describe Radiopharmaceutical Solutions research findings and conclusion.
Summary:
Get latest Market Research Reports on Radiopharmaceutical Solutions. Industry analysis & Market Report on Radiopharmaceutical Solutions is a syndicated market report, published as Global Radiopharmaceutical Solutions Market 2026 by Company, Regions, Type and Application, Forecast to 2032. It is complete Research Study and Industry Analysis of Radiopharmaceutical Solutions market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.